IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment
Preliminary results from the trial indicate a 39% overall response rate and a disease control rate of 94%.
09 July 2024
09 July 2024
Preliminary results from the trial indicate a 39% overall response rate and a disease control rate of 94%.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.